Mesenchymal Stem Cells With Adjuvant Dexamethasone in Patients With Alzheimer's Disease: A Phase IIa Trial.

ABSTRACT:

Background and purpose

This phase IIa trial assessed the safety and efficacy of mesenchymal stem cell (MSC) therapy for Alzheimer's disease (AD). An open-label extension (OLE) further explored the adjunctive role of dexamethasone.

Methods

MSCs (n=24) or a saline placebo (n=12) were administered intraventricularly three times at four-week intervals. In the OLE, MSCs and dexamethasone (15 mg, n=5) were administered to patients who received saline in phase IIa. Clinical parameters and cerebrospinal fluid (CSF) markers were evaluated.

Results

MSC therapy exhibited no significant clinical benefits, but was associated with reductions in CSF AD biomarkers (amyloid-beta, phosphorylated-tau, and total-tau) compared to placebo. The MSC group experienced more adverse events (fev

SUBMITTER: Lee NK 

PROVIDER: S-EPMC12599408 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature